Last reviewed 2026-04-23 · How we verify

CMAB807 Injection

CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses.

CMAB807 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity or reduce pathological immune responses. Used for Solid tumors (specific indication under investigation in Phase 3).

At a glance

Mechanism of action

While the exact molecular target of CMAB807 has not been widely disclosed in public literature, Shanghai Biomabs' pipeline suggests it is likely a checkpoint inhibitor or targeted immunotherapy. The drug is designed to modulate immune function through antibody-mediated mechanisms, potentially blocking inhibitory signals on T cells or targeting tumor-associated antigens to promote anti-tumor activity.

Approved indications

• Solid tumors (specific indication under investigation in Phase 3)

Common side effects

No common side effects on file.

Key clinical trials

• Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (PHASE3)
• Study of CMAB807 Post-change in Manufacturing Site and Prolia in Healthy Volunteers (PHASE1)
• Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• CMAB807 Injection CI brief — competitive landscape report
• CMAB807 Injection updates RSS · CI watch RSS
• Shanghai Biomabs Pharmaceutical Co., Ltd. portfolio CI